Phibro Animal Health Corp. (PAHC)
38.25
-0.33
(-0.86%)
USD |
NASDAQ |
Sep 04, 16:00
38.26
+0.01
(+0.03%)
After-Hours: 20:00
Phibro Animal Health SG&A Expense (TTM) : 318.12M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 318.12M |
| March 31, 2026 | 308.17M |
| December 31, 2025 | 298.20M |
| September 30, 2025 | 292.20M |
| June 30, 2025 | 289.48M |
| March 31, 2025 | 281.92M |
| December 31, 2024 | 270.54M |
| September 30, 2024 | 257.12M |
| June 30, 2024 | 259.78M |
| March 31, 2024 | 243.94M |
| December 31, 2023 | 241.25M |
| September 30, 2023 | 239.88M |
| June 30, 2023 | 226.39M |
| March 31, 2023 | 229.03M |
| December 31, 2022 | 224.47M |
| September 30, 2022 | 211.31M |
| June 30, 2022 | 206.41M |
| March 31, 2022 | 201.55M |
| December 31, 2021 | 198.15M |
| September 30, 2021 | 198.14M |
| June 30, 2021 | 196.51M |
| March 31, 2021 | 188.24M |
| December 31, 2020 | 187.44M |
| September 30, 2020 | 188.56M |
| June 30, 2020 | 187.64M |
| Date | Value |
|---|---|
| March 31, 2020 | 198.44M |
| December 31, 2019 | 192.52M |
| September 30, 2019 | 185.96M |
| June 30, 2019 | 181.39M |
| March 31, 2019 | 169.59M |
| December 31, 2018 | 169.87M |
| September 30, 2018 | 169.91M |
| June 30, 2018 | 167.95M |
| March 31, 2018 | 166.15M |
| December 31, 2017 | 154.22M |
| September 30, 2017 | 152.11M |
| June 30, 2017 | 150.30M |
| March 31, 2017 | 150.20M |
| December 31, 2016 | 158.34M |
| September 30, 2016 | 157.26M |
| June 30, 2016 | 156.38M |
| March 31, 2016 | 156.78M |
| December 31, 2015 | 155.29M |
| September 30, 2015 | 151.80M |
| June 30, 2015 | 148.72M |
| March 31, 2015 | 150.03M |
| December 31, 2014 | 148.25M |
| September 30, 2014 | 146.09M |
| June 30, 2014 | 143.98M |
| March 31, 2014 | 129.39M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Zoetis, Inc. | 2.378B |
| Merck & Co., Inc. | 11.14B |
| ANI Pharmaceuticals, Inc. | 324.76M |
| Corcept Therapeutics, Inc. | 556.47M |
| Veru, Inc. | 16.05M |